Summary
- Peloton Therapeutics has filed proposed terms for a $150 million IPO.
- The firm is advancing a pipeline of treatment candidates for kidney and other cancers.
- PLTX has achieved promising early stage trial results for its lead program.
- This idea was discussed in more depth with members of my private investing community, IPO Edge. Start your free trial today »
Quick Take
Peloton Therapeutics (PLTX) intends to raise $150 million in an IPO of its common stock, per an amended registration statement.
The company is advancing a pipeline of small molecule therapeutic candidates for the treatment of kidney cancer and other diseases.
PLTX has had quite promising trial results for its lead program. The firm has a strong investor syndicate though the IPO is a bit pricey.
